- Home
- VNDA
as 11-21-2024 4:00pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 270.2M | IPO Year: | 2006 |
| Target Price: | $15.50 | AVG Volume (30 days): | 643.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.46 - $6.75 | Next Earning Date: | 11-06-2024 |
| Revenue: | $190,858,000 | Revenue Growth: | -9.91% |
| Revenue Growth (this year): | 5.13% | Revenue Growth (next year): | 42.65% |
Stock Insider Trading Activity of Vanda Pharmaceuticals Inc. (VNDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | VNDA | Director | Nov 14 '24 | Sell | $5.17 | 5,000 | $25,863.00 | 44,857 |
Latest Vanda Pharmaceuticals Inc. News
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
New Strong Buy Stocks for November 14th
PR Newswire
9 days ago
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
GuruFocus.com
15 days ago
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ...
Associated Press Finance
15 days ago
Vanda: Q3 Earnings Snapshot
PR Newswire
15 days ago
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Simply Wall St.
16 days ago
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
Benzinga
20 days ago
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
The Wall Street Journal
21 days ago
Health Care Roundup: Market Talk
Compare VNDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.